Latest News about acute myeloid leukemia
Recent news which mentions acute myeloid leukemia
Cancer Drug Trials Put On Hold After Patients Died
June 17, 2023
From Benzinga
Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study
February 14, 2022
Tickers
MBRX
From Benzinga
FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial
January 21, 2022
Tickers
KURA
From Benzinga
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
December 14, 2021
Tickers
APTO
From Benzinga
See Why FDA Hit Red Light On Kura's Early-Stage Leukemia Trial
November 24, 2021
Tickers
KURA
From Benzinga
Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial
November 23, 2021
Tickers
APVO
From Benzinga
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
From Benzinga
GlycoMimetics' Lead Candidate Data Published In An Online Journal
September 24, 2021
Tickers
GLYC
From Benzinga
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
September 16, 2021
Tickers
NTLA
From Benzinga
Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial
September 15, 2021
From Benzinga
Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US
September 09, 2021
Tickers
VOR
From Benzinga
Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?
August 24, 2021
Tickers
BPTH
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free